In this issue:
Malignant neoplasms in biologic drug recipients
Biological exposure during conception and pregnancy
Adalimumab biosimilar in moderate-to-severe RA
Mavrilimumab vs golimumab in RA
Discontinuation after transition from infliximab to biosimilar
Rituximab for adult-onset IgA vasculitis (Henoch-Schönlein)
Secukinumab in active ankylosing spondylitis
Delaying abatacept in dermatomyositis and polymyositis
Long-term safety of adalimumab in IBD
Efficacy and safety of golimumab in CD
Vaccine response in infants exposed to biologics in utero
Please login below to download this issue (PDF)